AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00506779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by vein over 3 Hours every 21 Days
Study NCT02192567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5573a
Description: Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1.
Study NCT02215057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthesia
Description: topical anesthetic drops and Group 2
Study NCT02215057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthesia plus intracameral lidocaine 1%
Description: received topical anesthesia plus intracameral lidocaine 1%
Study NCT00344175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Study NCT00344175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Study NCT02695914 — intervention group
Intervention type: DRUG
Intervention: Compound Qingre Granule
Description: A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
Study NCT03371199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride tablets, 250 mg
Study NCT03371199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch tablets
Study NCT01623505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix
Description: Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
Study NCT01623505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicoderm patch combined with gum or inhaler
Description: Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter.
Study NCT01623505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicoderm patch
Description: Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
Study NCT02232971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon is given in three different doses according to three research days.
Study NCT02232971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: Placebo
Study NCT04377503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab 180 MG/ML
Description: Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
Study NCT04377503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 180 MG/ML
Description: Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
Study NCT04377503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
Study NCT04377503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
Study NCT01896687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler
Description: Electrotherapy
Study NCT01896687 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Scrambler
Description: Electrotherapy
Study NCT04679961 — intervention group
Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System (Apollo Medical Optics)
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
Study NCT03120364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of Oka/SK strain of live, attenuated zoster virus
Study NCT03120364 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Preparation of Oka/Merck strain of live, attenuated zoster virus
Study NCT04829266 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mental simulation
Description: Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
Study NCT04829266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental simulation
Description: Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
Study NCT01611766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Cytoreductive Surgery
Description: Complete Cytoreduction
Study NCT01611766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy
Description: 6 cycles of postoperative chemotherapy
Study NCT01611766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvage Chemotherapy
Description: 6 cycles of postoperative chemotherapy
Study NCT01084109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized meat
Description: Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
Study NCT01084109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal
Description: Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
Study NCT03434418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: 80 mg oral administration daily
Study NCT00798577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox Ophthalmic Solution
Description: Moxifloxacin 5mg/mL 3 times daily for 7 days
Study NCT00798577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSS placebo
Description: Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
Study NCT00250406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Stent
Description: triclosan-eluting ureteral stent
Study NCT00250406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral Stent
Description: Percuflex Plus Stent as the control
Study NCT03905668 — intervention group
Intervention type: OTHER
Intervention: Video Monitoring
Description: Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
Study NCT03905668 — intervention group
Intervention type: OTHER
Intervention: Accelerometer Monitoring
Description: Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
Study NCT03905668 — intervention group
Intervention type: OTHER
Intervention: Electromyographic Monitoring
Description: Patients may have electromyographic monitoring for up to seven days while in the ICU.
Study NCT03905668 — intervention group
Intervention type: OTHER
Intervention: Noise Level Monitoring
Description: Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
Study NCT03905668 — intervention group
Intervention type: OTHER
Intervention: Light Level Monitoring
Description: Patients may have light level monitoring for up to seven days while in the ICU.
Study NCT04154371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography-controlled virtual and augmented reality using serious gaming
Description: Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
Study NCT02598505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Study NCT02598505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01672528 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
Study NCT01672528 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
Study NCT03574415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets
Study NCT03574415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets
Study NCT03574415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets
Study NCT04384432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy with Thoracic mobility exercise
Description: Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
Study NCT04384432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routıne Physıcal therapy
Description: Exercise for Chronic Neck Pain
Study NCT01946412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT01560611 — intervention group
Intervention type: DEVICE
Intervention: Near infrared spectroscopy
Study NCT00222417 — intervention group
Intervention type: PROCEDURE
Intervention: myringoplasty
Description: Myringoplasty is an operative procedure to close tympanic membrane perforations.
Study NCT00222417 — intervention group
Intervention type: PROCEDURE
Intervention: Stapes surgery
Description: Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
Study NCT02670928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
Study NCT02670928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
Study NCT01802099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enteral nutrition
Study NCT01802099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parenteral nutrition
Study NCT00689897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture, Deqi
Description: Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
Study NCT00689897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture, Non-Deqi
Description: After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
Study NCT01616277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
Study NCT01954888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind technique
Description: A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
Study NCT01954888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided technique
Description: A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
Study NCT00781963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based cognitive behavioral therapy for insomnia
Description: Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
Study NCT00781963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive sleep education
Description: Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
Study NCT04446871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
Study NCT04446871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
Study NCT01768312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes
Study NCT01768312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine ophthalmic solution
Description: 1 drop twice/day for 12 weeks to both eyes
Study NCT05382988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: The experimental group was required to take SZC 10g at 6 am on the day of surgery.
Study NCT00654953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
Study NCT00654953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.
Study NCT00654953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.
Study NCT00654953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
Study NCT00546234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: 18 mcg daily via Handihaler
Study NCT00546234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting beta agonist
Description: Turbohaler, 6 \& 12 mcg
Study NCT01683084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT01683084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04438772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia
Description: Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
Study NCT04438772 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia
Description: Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
Study NCT03289871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excilor
Study NCT03289871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl 5%
Study NCT01679561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralipid
Description: intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
Study NCT04201938 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Symbiter-Omega
Description: Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
Study NCT04201938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00525239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
Description: 100 mg, twice daily, for four weeks
Study NCT01319019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Comparison of different doses and dosing regimens of the drug
Study NCT01319019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Positive control
Study NCT01319019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study NCT00745381 — intervention group
Intervention type: OTHER
Intervention: questionnaire, Blood specimens
Description: All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
Study NCT02064205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 12.5 g polydextrose
Description: Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
Study NCT01616277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose
Study NCT02064205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12.5 g polydextrose
Description: Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
Study NCT02064205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose syrup
Description: Glucose syrup is used a control product for the polydextrose
Study NCT02064205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose syrup
Description: Glucose syrup is used a control product for the polydextrose